Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)Diane M Da Silva, Danielle M Enserro, Jyoti S Mayadev, et al.
Gynecologic Oncology|July 15, 2014
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group StudyMatthew A Powell, Michael W Sill, Paul J Goodfellow, et al.
Gynecologic Oncology|July 19, 2015
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyDavid Bender, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.
Gynecologic Oncology|August 28, 2012
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Heather A Lankes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyKristina W Thiel, Eric J Devor, Virginia L Filiaci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyBradley J Monk, Andrea Facciabene, William E Brady, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2021
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerMelissa A Merritt, Howard D Strickler, Alan D Hutson, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
Pageof 7